TrialIbrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Trial details
- Registry ID
- NCT05399641
- Phase
- Phase 3
Drug research
Ibrexafungerp
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as SCY-078
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisNCT05399641 | SCYX | Phase 3 | Completed | 2023-05-16Actual |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentNCT03059992 | SCYX | Phase 3 | Completed | 2023-08-25Actual |
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Trial details
- Registry ID
- NCT03059992
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |